Objective:To explore improving effect of Danqi soft capsule on hemorheology in patients with coronary heart disease (CHD) and its myocardial protection effect .Methods:A total of 84 CHD patients treated in our hos‐pital from Dec 2013 to Dec 2014 were enrolled .They were randomly divided into routine treatment group (n=42) and combined treatment group (n=42 ,received Danqi soft capsule therapy based on routine treatment group ) .He‐morheological indexes ,ECG and inflammatory factor levels [C reactive protein (CRP) ,tumor necrosis factor α(TNF‐α)] were measured and compared between two groups before and after treatment .Results:Compared with before treatment , above hemorheological indexes significantly reduced in both groups after treatment ( P< 0.05 all) ,compared with routine treatment group ,there were significant reductions in high shear whole blood viscosity [ (5.12 ± 0.73) mPa/s vs .(4.47 ± 0.86) mPa/s] ,low shear whole blood viscosity [ (7.36 ± 1.32) mPa/s vs .(6.21 ± 1.03) mPa/s] ,plasma viscosity [ (1.47 ± 0.31) mPa/s vs .(1.31 ± 0.25) mPa/s] ,erythrocyte aggregation index [ (3.53 ± 0.45) vs .(2.93 ± 0.26)] and fibrinogen level [ (2.95 ± 0.28) g/L vs .(2.08 ± 0.24) g/L] in combined treatment group , P< 0.05 all .Total effective rate on ECG in combined treatment group was significantly higher than that of routine treatment group (85.71% vs .57.14% ,P<0.05) .Compared with before treatment ,CRP and TNF‐αlevels significantly reduced in both groups after treatment ( P<0.05 all) ,compared with routine treatment group ,there were significant reductions in levels of CRP [ (6.52 ± 1.61) mg/L vs .(5.18 ± 1.25) mg/L] and TNF‐α [ (283.28 ± 18.28) pg/ml vs .(245.08 ± 12.24) pg/ml] in combined treatment group , P<0.05 all .Conclusion:Danqi soft capsule combined routine treatment can significantly improve hemorheology and reduce related inflamma‐tory factor levels ,possess myocardial protection effect in CHD patients ,which is worth extending .

Objective To study the expression of SARS-associated coronavirus nucleocapsid(N) gene in Pichia pastoris and to obtain recombinant N protein with good biological activity.Methods The gene encoding the full N protein of SARS-CoV was amplified by PCR and cloned into Pichia pastoris expression vector pPICZA.The recombinant expression plasmid pPICZA/N was transformed into X-33,KM71H and GS115. The positive insert transformants were screened,cultured and induced by methanol.The recombinant protein was further purified with Ni affinity chromatography.Antigen activity was detected with anti-N monoclonal antibody,polyclonal antibody and sera from SRAS patients.Results SDS-PAGE and immunological analysis demonstrated that only Pichia pastoris transformants KM71H/pPICZA/N and X-33/pPICZA/N expressed Mr 70 000 fusion protein with special antigenicity.Conclusion SARS-CoV N protein expression in Pichia pastoris has been achieved,establishing the basis for further study of biological and immunological function of N antigen.

To prepare and study the pharmacokinetics and release bioavailability in olunteers and concentrations in plasma in patients. METHODS: Ethylcellulose was used matrix in phase separation-coacervation for preparation of microencapsulation. The release experiments were performed in a rotating shaker. The isoniazid concentration in plasma was determined by spectrophotometrical method following a single oral dose of sustained-release cupsule and ordinary tablet respectively given to 10 volunteers in a open randomized cross-over test. MCP86 was used to process main pharmacokinetic parameters. RESULTS: The sustained-release of capsule and ordinary teblet in vitro, T50 was 1 h and 0.032 h respectively. The drug in sustained-release capsule was sustained release over 10 h. The main parameters in body: ordinary tablets: cmax=11.12 μgml-1, tmax=1.41 h, K=0.201 h-1; sustained release capsule: cmax=4.99 μgml-1, tmax=1.80 h, K=0.03 h-1. The concentration of blood at 36 h was (0±0)μgml-1 and 1.63 μgml-1 respectively. Except tmax, there was significant difference between the two fomulations (P＜0.01). The concentration of blood in patient at 1.5 h and 36 h. ordinary tablet and sustained-release capsule respectively were (8.24±2.60)μgml-1, (0±0)μgml-1and (3.69±0.86)μgml-1, (2.09±0.56)μgml-1. CONCLUSION: The sustained-release capsule will play an important part in prevention and treatment of tuberculosis as the result of its reasonable formulation and simple technology.

Objective To investigate the clinical feature on pulmonary complications after renal transplantation,in order to provide the evidence of prevention and treatment of pulmonary complications.Methods The clinical data of 125 renal transplant re-cipients in the First Affiliated Hospital of Chongqing Medical University from December 2006 to December 2011 were studied retro-spectively.To analyze and summarize the clinical characteristics of postoperative pulmonary complications including the incidence, the time of onset,etiology or risk factors,treatment,outcome,et al.Results Twenty-three patients(18.4%)developed pulmonary complications after renal transplantation.The most frequent complication was pulmonary infection(n = 22,17.6%),followed by pleural effusion(n=12,9.6%),pulmonary edema(n= 7,5.6%),respiratory tract bleeding(n=4,3.2%),acute lung graft versus host reaction(n=1,0.8%)and atelectasis(n= 1,0.8%).Conclusion Pulmonary infection,pleural effusion and pulmonary edema are common pulmonary complications after renal transplantation.Patients who develop pulmonary infection and pulmonary edema have a poor prognosis.

Objective To provide an information monitoring software for therapy drug,which can automatically construct safe concentration scope,statistically analyses data,query and input data.Methods TDMIS is developed by Powerbuilder 9.0 and is run in WIN 98 or the copy over it.2062 cases are analyzed through TDMIS and a safe concentration scope is set.Conclusion TDMIS is a practical software.It can make drug prescription standardized,computerized and easy to be statistically analyzed.The working efficiency and quality of clinical apothecary are greatly improved.

Objective To observe MSCT features of partially or completely low enhancement of pancreas neuroendocrine tumors (PNENs).Methods The clinical data and MSCT features before pancreatectomy in 44 patients with confirmed PNENs were retrospectively reviewed.The MSCT findings were evaluated including tumor size, location, margin, density, intratumoral structure, bile duct and pancreatic ductal dilation and distant metastasis.Tumors were classified into complete enhancement type, partially or completely low enhancement type for further comparative analysis based on MSCT enhancement during pancreatic stage.Results A total of 56 PNENs in 44 patients were found, and there were 31 partially or completely low enhanced PNENs and 25 completely enhanced PNENs.The former were larger than the latter [mean tumor size, (3.3±2.2)cm vs (1.4±0.9) cm], and irregular shape and cystic components within tumors were more often observed (all P<0.05).There were no significant differences between the two types of PNENs in terms of gender, the presence of functional tumor, tumor location, clear tumor margin, intratumoral calcification, bile and pancreatic duct dilation and metastasis.76.0%(19/25) of completely enhanced PNENs reached peak enhancement in arterial phase, and 71.0%(22/31) of low enhancement PNENs reached peak in pancreatic phase.Enhanced intratumoral blood vessels in the arterial phase were more frequent in low enhancement PNENs, and the difference was statistically significant (P<0.05).There were significant differences on pathological grade between the two types of PNENs (G1=21,G2=4,G3=0 vs G1=18,G2=5, G3=8), and the difference was statistically significant (P<0.05).Conclusions Compared with complete enhancement PNENs, partially or completely low enhancement PNENs had bigger size, irregular shape, and cystic component.Intratumoral blood vessels in the arterial phase were observed, peak enhancement arrived later and the pathological grade was higher.

General Policies of Nomenclature for Biological Products in China were studied,aimed at establishing and perfecting the system of Chinese approved biologic name.By means of analysis of the current situation and existing problems of nomenclature for biological products and the development trend of new biotherapeutics.It is sufficiently studied on the existing leading international drug generic naming system,and the specific suggestions on revision of the General Policies of Nomenclature for Biological Products in China based on the naming principles of WHO INN and Chinese language recognition were put forward.

The proto-oncogene, c-kit gene, widely expresses on the mast cell, melanoeyte, haemopoietic stem cell, intestinal cell of cajal and germoeyte. Recent researches have revealed the relationship between the e-kit gene and the carcinogenesis, proliferation, infiltration and metastasis of some malignant tumor. This article aimed to make a review of its biological function, lab and clinical research advancement in the digestive tract tumor.

To support the ongoing health reform in China,Chongqing municipal government made the decision in 2008 "Building Healthy Chongqing" ,and pinpointed for the first time regional development as a key goal.In line with this situation,the hospital proposed such hypothesis changes as from "disease hypothesis to "health hypothesis",from "illness oriented" to "capability oriented",and from "shaping development" to "adaptive development",as well as from one-sided efforts of medical staff to minimize casualty to joint efforts with patients to safeguard life and health.Focusing on these four strategic shifts,the hospital works in developing its "technical attraction,service capacity,innovation capacity,and emergency assurance capability,and management soft power",aiming at building a sustainable hospital in its development.

Stem cells are those with long-term self-renewal and produce differentiated cells at least one end of the cell capacity. Stem cell transplantation can be used for the treatment of many kind of liver diseases which includes acute liver failure, inherited metabolic liver diseases, as well as end-stage liver disease. This Article summarizes the types of stem cell types applied for treatment of liver diseases, stem cell tracing technology, as well as the clinical application of stem cells. It also discusses the problems existed and the research focus.